Literature DB >> 3129997

IgG subclass and light chain distribution of anticardiolipin and anti-DNA antibodies in systemic lupus erythematosus.

A E Gharavi1, E N Harris, M D Lockshin, G R Hughes, K B Elkon.   

Abstract

The IgG subclass and light chain distribution of anticardiolipin and anti-DNA antibodies were determined in serum samples from patients with systemic lupus erythematosus. With an enzyme linked immunosorbent assay (ELISA) and mouse monoclonal antibodies to individual subclasses, significant differences in the distributions of IgG2, IgG3, and IgG4 subclasses were observed between anticardiolipin and anti-DNA antibodies. Whereas anti-DNA antibodies were predominantly IgG1 and IgG3, all subclasses of anticardiolipin were detected with a prevalence ranging from 34% (IgG3) to 57% (IgG1). Clinical complications were found slightly more frequently (83%) in patients with sera containing the non or weak complement fixing subclasses (IgG2 and IgG4) than in patients with sera containing complement fixing (IgG1 and IgG3) subclasses (62%). Light chain analysis by ELISA showed a trend towards use of kappa chains for anti-DNA and lambda chains for anticardiolipin antibodies. These findings further emphasise the differences between anti-DNA and anticardiolipin antibodies in terms of their origins and potential mechanisms for producing tissue injury.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3129997      PMCID: PMC1003508          DOI: 10.1136/ard.47.4.286

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  14 in total

1.  The natural history of systemic lupus erythematosus: an approach to its study through chronic biologic false positive reactors.

Authors:  J E MOORE; W B LUTZ
Journal:  J Chronic Dis       Date:  1955-03

2.  DNA antibody class, subclass, and complement fixation in systemic lupus erythematosus with and without nephritis.

Authors:  R D Sontheimer; J N Gilliam
Journal:  Clin Immunol Immunopathol       Date:  1978-08

3.  The gammaG subclass of antinuclear and antinucleic acid antibodies.

Authors:  P H Schur; M Monroe; N Rothfield
Journal:  Arthritis Rheum       Date:  1972 Mar-Apr

Review 4.  B cell subsets and differential responses to mitogens.

Authors:  J P McKearn; J W Paslay; J Slack; C Baum; J M Davie
Journal:  Immunol Rev       Date:  1982       Impact factor: 12.988

5.  Immunoglobulin classes and IgG subclasses of human antinuclear antibodies. A correlation of complement fixation and the nephritis of systemic lupus erythematosus.

Authors:  E M Puritz; W J Yount; M Newell; P D Utsinger
Journal:  Clin Immunol Immunopathol       Date:  1973-11

6.  Natural infection of man with group A streptococci. Levels; restriction in class, subclass, and type; and clonal appearance of polysaccharide-group-specific antibodies.

Authors:  W F Riesen; F Skvaril; D G Braun
Journal:  Scand J Immunol       Date:  1976       Impact factor: 3.487

7.  Affinity purified anti-cardiolipin and anti-DNA antibodies.

Authors:  E N Harris; A E Gharavi; A Tincani; J K Chan; H Englert; P Mantelli; F Allegro; G Ballestrieri; G R Hughes
Journal:  J Clin Lab Immunol       Date:  1985-08

8.  Recurrent sinopulmonary infection and impaired antibody response to bacterial capsular polysaccharide antigen in children with selective IgG-subclass deficiency.

Authors:  D T Umetsu; D M Ambrosino; I Quinti; G R Siber; R S Geha
Journal:  N Engl J Med       Date:  1985-11-14       Impact factor: 91.245

9.  Complement fixation by anti-dsDNA antibodies in SLE: measurement by radioimmunoassay and relationship with disease activity.

Authors:  C G Mackworth-Young; J K Chan; C C Bunn; G R Hughes; A E Gharavi
Journal:  Ann Rheum Dis       Date:  1986-04       Impact factor: 19.103

10.  Monoclonal immunoglobulin M lambda coagulation inhibitor with phospholipid specificity. Mechanism of a lupus anticoagulant.

Authors:  P Thiagarajan; S S Shapiro; L De Marco
Journal:  J Clin Invest       Date:  1980-09       Impact factor: 14.808

View more
  15 in total

1.  IgG anti-cardiolipin antibodies in murine lupus.

Authors:  A E Gharavi; R C Mellors; K B Elkon
Journal:  Clin Exp Immunol       Date:  1989-11       Impact factor: 4.330

2.  Anticardiolipin antibodies in systemic lupus erythematous.

Authors:  N Snowden; P Wilson; R Pumphrey
Journal:  Ann Rheum Dis       Date:  1989-01       Impact factor: 19.103

3.  Differential diagnosis of lupus and primary membranous nephropathies by IgG subclass analysis.

Authors:  Young Soo Song; Kyueng-Whan Min; Ju Han Kim; Gheun-Ho Kim; Moon Hyang Park
Journal:  Clin J Am Soc Nephrol       Date:  2012-09-27       Impact factor: 8.237

4.  Anticardiolipin antibodies in patients from Malaysia with systemic lupus erythematosus.

Authors:  H W Jones; R Ireland; G Senaldi; F Wang; M Khamashta; A J Bellingham; K Veerapan; G R Hughes; D Vergani
Journal:  Ann Rheum Dis       Date:  1991-03       Impact factor: 19.103

5.  Clinical manifestations and antiphosphatidylserine antibodies in patients with systemic lupus erythematosus: is there an association?

Authors:  Mehmet Sahin; Nursen Duzgun; Sevket Ercan Tunc; Huseyin Tutkak
Journal:  Clin Rheumatol       Date:  2006-04-06       Impact factor: 2.980

6.  IgG2 subclass restriction of anti-beta 2 glycoprotein 1 antibodies in autoimmune patients.

Authors:  J Arvieux; B Roussel; D Ponard; M G Colomb
Journal:  Clin Exp Immunol       Date:  1994-02       Impact factor: 4.330

7.  Immunoglobulin class and IgG subclass distribution of anticardiolipin antibodies in patients with systemic lupus erythematosus and associated disorders.

Authors:  S Loizou; C Cofiner; A P Weetman; M J Walport
Journal:  Clin Exp Immunol       Date:  1992-12       Impact factor: 4.330

8.  MRL/lpr-->severe combined immunodeficiency mouse allografts produce autoantibodies, acute graft-versus-host disease or a wasting syndrome depending on the source of cells.

Authors:  D Ashany; J J Hines; A E Gharavi; J Mouradian; J Drappa; K B Elkon
Journal:  Clin Exp Immunol       Date:  1992-12       Impact factor: 4.330

9.  Isotypic distribution of anti-pyruvate dehydrogenase antibodies in patients with primary biliary cirrhosis and their family members.

Authors:  R Maran; M Dueymes; Y Adler; Y Shoenfeld; P Youinou
Journal:  J Clin Immunol       Date:  1994-09       Impact factor: 8.317

10.  Precipitating anti-dsDNA peptide repertoires in lupus.

Authors:  J J Wang; A D Colella; D Beroukas; T K Chataway; T P Gordon
Journal:  Clin Exp Immunol       Date:  2018-10-11       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.